Literature DB >> 16840597

The laboratory school protocol: its origin, use, and new applications.

Sharon B Wigal1, Timothy L Wigal.   

Abstract

OBJECTIVE: ADHD is the most common childhood psychiatric disorder, with impairments seen in home and academic settings. To investigate such impairments in a school-like setting, the laboratory school protocol (LSP) was developed at the University of California, Irvine.
METHOD: This model provides a rigorously controlled environment to examine pharmacodynamic and pharmacokinetic aspects of responses to treatment. A key principle of this methodology is to exercise tight control of the timing and context of measurements by establishing a cycle of activities repeated across each study day. In addition, the LSP approach has been extended to both younger and older populations than the typically studied school-aged group. This extension requires corresponding modifications in measures to characterize drug efficacy and to allow evaluation of ADHD symptoms in a highly standardized setting.
RESULTS: This article provides guidelines for employing the LSP for the assessment of medication effects for both preschool and adolescent/adult populations.
CONCLUSION: The LSP can be modified to form either an Adult Workplace Environment or a Preschool Assessment Laboratory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840597     DOI: 10.1177/1087054705286049

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  35 in total

1.  Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Tim Wigal; Sabrina Schuck; Matthew Brams; David Williamson; Robert B Armstrong; H Lynn Starr
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-13       Impact factor: 2.576

Review 2.  New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Samuele Cortese; Giulia D'Acunto; Eric Konofal; Gabriele Masi; Benedetto Vitiello
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

3.  Phase synchronization of oxygenation waves in the frontal areas of children with attention-deficit hyperactivity disorder detected by optical diffusion spectroscopy correlates with medication.

Authors:  Sharon B Wigal; Chiara M Polzonetti; Annamarie Stehli; Enrico Gratton
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

4.  A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Laurence L Greenhill; Earl Nordbrock; Daniel F Connor; Scott H Kollins; Akwete Adjei; Ann Childress; Annamarie Stehli; Robert J Kupper
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-12       Impact factor: 2.576

5.  Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.

Authors:  Akwete Adjei; Nathan S Teuscher; Robert J Kupper; Wei-Wei Chang; Laurence Greenhill; Jeffrey H Newcorn; Daniel F Connor; Sharon Wigal
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-12       Impact factor: 2.576

Review 6.  Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?

Authors:  Raman Baweja; Richard E Mattison; James G Waxmonsky
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

Review 7.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study.

Authors:  Sharon B Wigal; Ann C Childress; Heidi W Belden; Sally A Berry
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-01-05       Impact factor: 2.576

9.  Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis.

Authors:  Edmund J S Sonuga-Barke; Pol Van Lier; James M Swanson; David Coghill; Sharon Wigal; Mieke Vandenberghe; Simon Hatch
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-06       Impact factor: 4.785

10.  A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.

Authors:  Sharon B Wigal; Scott H Kollins; Ann C Childress; Liza Squires
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2009-06-09       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.